Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Cash & Equivalents (2016 - 2025)

Rein Therapeutics (RNTX) has disclosed Cash & Equivalents for 10 consecutive years, with $4.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Cash & Equivalents fell 77.07% to $4.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $4.0 million, a 77.07% decrease, with the full-year FY2024 number at $12.9 million, down 25.69% from a year prior.
  • Cash & Equivalents was $4.0 million for Q3 2025 at Rein Therapeutics, down from $5.7 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $21.9 million in Q2 2024 to a low of $3.6 million in Q4 2021.
  • A 5-year average of $10.4 million and a median of $7.8 million in 2023 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: skyrocketed 233.33% in 2023, then tumbled 77.07% in 2025.
  • Rein Therapeutics' Cash & Equivalents stood at $3.6 million in 2021, then surged by 44.28% to $5.2 million in 2022, then surged by 233.33% to $17.3 million in 2023, then decreased by 25.69% to $12.9 million in 2024, then tumbled by 68.53% to $4.0 million in 2025.
  • Per Business Quant, the three most recent readings for RNTX's Cash & Equivalents are $4.0 million (Q3 2025), $5.7 million (Q2 2025), and $7.4 million (Q1 2025).